



(11) **EP 2 368 887 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07D 249/04 ^(2006.01) **C07D 413/12** ^(2006.01)
A61K 31/4192 ^(2006.01) **A61P 3/06** ^(2006.01)

(48) Corrigendum issued on:
16.04.2014 Bulletin 2014/16

(45) Date of publication and mention
of the grant of the patent:
26.02.2014 Bulletin 2014/09

(21) Application number: **11168642.4**

(22) Date of filing: **07.11.2008**

(54) **1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS**

1,2,3-TRIAZOLDERIVATE ZUR VERWENDUNG ALS INHIBITOREN VON STEAROYL-COA-DESATURASE

DÉRIVÉS DE 1,2,3-TRIAZOLE DESTINÉS À ÊTRE UTILISÉS COMME INHIBITEURS DE LA STÉAROYL-COA DÉSATURASE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**
Designated Extension States:
AL BA MK RS

(30) Priority: **09.11.2007 GB 0722077**

(43) Date of publication of application:
28.09.2011 Bulletin 2011/39

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
08846247.8 / 2 207 770

(73) Proprietor: **GlaxoSmithKline LLC**
Wilmington, Delaware 19808 (US)

(72) Inventors:
• **Bouillot, Anne, Marie, Jeanne**
91951 Les Ulis (FR)

• **Laroze, Alain**
91951 Les Ulis (FR)
• **Trottet, Lionel**
91951 Les Ulis (FR)

(74) Representative: **Hillier, Mark**
GlaxoSmithKline
Global Patents (CN9-25.1)
980 Great West Road
GB-Brentford, Middlesex TW8 9GS (GB)

(56) References cited:
WO-A-2005/011657 WO-A-2008/138917
WO-A1-2005/000821

• **CALDERONE, V. ET AL.:** "1,2,3-Triazol-carboxanilides and 1,2,3-triazol-(N-benzyl)-carboxamides as BK-potassium channel activators. XII", **EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY**, vol. 43, no. 11, 7 March 2008 (2008-03-07), pages 2618-2626, XP002513784,

EP 2 368 887 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).